Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Adversity in University: Cyberbullying and Its Impacts on Students, Faculty and Administrators.

Cassidy W, Faucher C, Jackson M.

Int J Environ Res Public Health. 2017 Aug 8;14(8). pii: E888. doi: 10.3390/ijerph14080888.

2.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team.

Gastroenterology. 2010 Nov;139(5):1602-11, 1611.e1. doi: 10.1053/j.gastro.2010.07.059. Epub 2010 Aug 16.

PMID:
20723545
3.

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators.

Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6. Erratum in: Lancet. 2010 Oct 9;376(9748):1224. SPRINT-1 investigators [added]; multiple investigator names added.

PMID:
20692693
4.

Factors influencing acceptance of influenza vaccination given in an ED.

Cassidy W, Marioneaux DM, Windham AF, Manning S, Fishbein D, Horswell RL.

Am J Emerg Med. 2009 Nov;27(9):1027-33. doi: 10.1016/j.ajem.2008.05.014.

PMID:
19931746
5.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team.

N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027.

7.

Development and evaluation of a standardized questionnaire for identifying adverse events in vaccine clinical trials.

Coplan P, Chiacchierini L, Nikas A, Shea J, Baumritter A, Beutner K, Cassidy W, Sawyer M, Watson B, Heyse J, Guess H.

Pharmacoepidemiol Drug Saf. 2000 Nov;9(6):457-71. doi: 10.1002/1099-1557(200011)9:6<457::AID-PDS529>3.0.CO;2-R.

PMID:
19025852
8.

Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.

Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW; Protocol 009 Study Group.

Vaccine. 2007 Feb 26;25(10):1877-83. Epub 2006 Oct 30.

PMID:
17227688
9.
10.

A comprehensive patient assessment and physician reminder tool for adult immunization: effect on vaccine administration.

Fishbein DB, Willis BC, Cassidy WM, Marioneaux D, Winston CA.

Vaccine. 2006 May 1;24(18):3971-83. Epub 2006 Feb 21.

PMID:
16569468
11.

Determining indications for adult vaccination: patient self-assessment, medical record, or both?

Fishbein DB, Willis BC, Cassidy WM, Marioneaux D, Bachino C, Waddington T, Wortley P.

Vaccine. 2006 Feb 6;24(6):803-18. Epub 2005 Aug 15.

PMID:
16455167
12.

Acute hepatitis E infection in a visitor to Louisiana.

Walker JE Jr, Brown TM, Hagood TL, Cassidy WM.

South Med J. 2005 Jul;98(7):721-2.

PMID:
16108241
13.

Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.

Luo S, Cassidy W, Jeffers L, Reddy KR, Bruno C, Howell CD.

Clin Gastroenterol Hepatol. 2005 May;3(5):499-506.

PMID:
15880320
14.

Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment.

Pradhan MM, Horswell R, Jones G, Ramsey JL, Cassidy W.

Dig Dis Sci. 2005 Apr;50(4):714-8.

PMID:
15844707
15.
16.

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR.

Hepatology. 2004 Jun;39(6):1702-8.

PMID:
15185312
17.

Recombivax-HB: perspectives past, present and future.

Venters C, Graham W, Cassidy W.

Expert Rev Vaccines. 2004 Apr;3(2):119-29. Review.

PMID:
15056038
18.

Adolescent hepatitis B vaccination. A review.

Cassidy WM.

Minerva Pediatr. 2001 Dec;53(6):559-66. Review.

PMID:
11740438
19.

Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.

Levaux HP, Schonfeld WH, Pellissier JM, Cassidy WM, Sheriff SK, Fitzsimon C.

Pediatrics. 2001 Aug;108(2):317-25.

PMID:
11483794
20.

Factors associated with student participation in a school-based hepatitis B immunization program.

Goldstein ST, Cassidy WM, Hodgson W, Mahoney FJ.

J Sch Health. 2001 May;71(5):184-7.

PMID:
11393930

Supplemental Content

Loading ...
Support Center